Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,140.00
+80.00 (1.58%)
At close: Aug 3, 2026

Sinil Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
6,9517,53114,30113,64112,1576,679
Depreciation & Amortization
5,9915,9915,6075,3614,4324,536
Loss (Gain) From Sale of Assets
24.3324.33-3.72641.55-221.3-14
Asset Writedown & Restructuring Costs
-108.28-108.28-31792.08-14.5
Loss (Gain) From Sale of Investments
-1.34-1.3426.81532.61373.44-115.48
Provision & Write-off of Bad Debts
34.2134.21797.59446.86409.12160.62
Other Operating Activities
873.66-191.63,161-408.832,9032,102
Change in Accounts Receivable
452452855.221,095-3,247161.49
Change in Inventory
-147.89-147.89-369.61-2,304-3,487236.85
Change in Accounts Payable
-446.88-446.88-113.72-1,2711,8401,210
Change in Other Net Operating Assets
-4,174-1,548-1,541-2,587-1,563-3,779
Operating Cash Flow
9,44911,58922,68915,15413,68811,163
Operating Cash Flow Growth
-50.48%-48.92%49.72%10.72%22.61%0.92%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,853-3,145-10,362-13,604-10,351-3,343
Sale of Property, Plant & Equipment
214.87-74.92122.76316.6145.68
Sale (Purchase) of Intangibles
-777.46-767.92-94.64-57-27.5-285.65
Investment in Securities
-1,082-971.61-13,2682,510-4,880-3,103
Other Investing Activities
45.632176.53-291.662.27-95
Investing Cash Flow
-5,403-4,803-23,473-11,319-14,880-6,665

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---22,578--
Total Debt Issued
---22,578--
Short-Term Debt Repaid
----22,578--
Long-Term Debt Repaid
--149.49-147.23-154.09-133.75-127.98
Total Debt Repaid
-146.09-149.49-147.23-22,732-133.75-127.98
Net Debt Issued (Repaid)
-146.09-149.49-147.23-154.09-133.75-127.98
Repurchase of Common Stock
----73.39-104.49-168.43
Dividends Paid
-2,196-2,196-1,965-1,112-1,081-1,051
Other Financing Activities
222222-2492--0
Financing Cash Flow
-2,120-2,124-2,136-1,248-1,319-1,347

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-91.787.544.83-11.37114.9425.44
Miscellaneous Cash Flow Adjustments
-0---0--
Net Cash Flow
1,8334,670-2,8762,576-2,3963,176

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
5,5958,44412,3271,5513,3367,820
Free Cash Flow Growth
-48.03%-31.50%694.85%-53.52%-57.34%245.93%
Free Cash Flow Margin
6.81%10.48%13.78%1.74%4.17%12.66%
Free Cash Flow Per Share
484.03730.461066.39134.13299.94695.63
Levered Free Cash Flow
460.275,3098,588-2,857148.738,141
Unlevered Free Cash Flow
471.335,3218,605-2,840152.528,147

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
17.7119.7126.9726.136.059.72
Cash Income Tax Paid
2,6463,145468.263,081772.841,113
Change in Working Capital
-4,317-1,691-1,169-5,067-6,457-2,170